FGF21’s multimodal mechanisms (neuroprotection, anti-inflammation, metabolism) and favorable safety profile make it superior to single-target growth factors (e.g., BDNF, VEGF) for ischemic stroke therapy [30]. The gene discussed is FGF21; the disease is ischemic stroke.